论文部分内容阅读
目的观察舒利迭治疗稳定期中重度慢性阻塞性肺疾病(COPD)的疗效。方法将明确诊断的10O例COPD患者随机分为两组:分别是对照组和试验组,给对照组进行已下的基础治疗:祛痰、抗感染、解痉平喘等;试验组也给予和对照组一样的基础治疗,另外加舒利迭50μg/250μg剂型,1吸/次,2次/d,疗程为3个月。比较两组临床疗效,评价治疗前后血气分析结果。结果治疗组的总有效率显著高于对照组,两组疗效比较差异具有统计学意义(P<0.05),治疗后,治疗组患者的PaO2、PaCO2的效果比对照组效果要明显显著,差异有统计学意义(P<0.05),吸入舒利迭无明显的毒副作用。结论联合应用舒利迭(沙美特罗/丙酸氟替卡松)治疗对稳定期慢性阻塞性肺疾病(COPD)患者肺功能有明显的改善作用。
Objective To observe the effect of seretide on stable chronic obstructive pulmonary disease (COPD). Methods A total of 10O patients with definite diagnosis of COPD were randomly divided into two groups: the control group and the experimental group, and the control group underwent basic treatment: expectorant, anti-infective, antispasmodic and antiasthmatic; the experimental group was also given the control group The same basic treatment, plus seretide 50μg / 250μg dosage form, 1 suction / time, 2 times / d, treatment for 3 months. The clinical efficacy of the two groups were compared to evaluate the blood gas analysis results before and after treatment. Results The total effective rate of the treatment group was significantly higher than that of the control group, and the difference between the two groups was statistically significant (P <0.05). After treatment, PaO2 and PaCO2 in the treatment group were significantly better than those in the control group Statistical significance (P <0.05), inhaled Seretide no obvious side effects. Conclusions The combined application of seretide (salmeterol / fluticasone propionate) has a significant effect on pulmonary function in patients with stable chronic obstructive pulmonary disease (COPD).